Continuing a trend that began in June, the largest biopharma deals of 2020 have all occurred this summer, led by the $6.3 billion global partnership on cancer immune therapies between Tango Therapeutics Inc. and Gilead Sciences Inc. earlier this month.
As of Aug. 13, more than 90,000 patients hospitalized in the U.S. with COVID-19 already had been given access to convalescent plasma through a national expanded use protocol (EAP) sponsored by the Mayo Clinic. The FDA’s decision Sunday to grant emergency use authorization (EUA) for the potential therapy will further expand access to convalescent plasma for hospitalized patients throughout the country at a time when fully approved COVID-19 treatments are nonexistent and even EUAs are few and far between.
DUBLIN – Adrenomed AG has reported encouraging, albeit limited, data for its antibody adrecizumab in eight COVID-19 patients in Germany with life-threatening acute respiratory distress syndrome (ARDS). The drug was made available on a named-patient basis to critically ill patients undergoing mechanical ventilation.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amneal, Capricor, EMD Serono, Gyroscope, Imara, Knight, Metacrine, Regenxbio, Sarepta, Therapeuticsmd.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Brainsway, Guardant Health, Helixbind.
Through the use of sequencing data, researchers in Hong Kong presented a case study providing the strongest evidence yet that individuals can become reinfected with SARS-CoV-2 after clearing a first infection.
RSS
